Aspire Biopharma (NASDAQ:ASBP) Posts Quarterly Earnings Results

Aspire Biopharma (NASDAQ:ASBP) issued its quarterly earnings data on Friday. The company reported ($20.57) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter.

Aspire Biopharma Stock Down 4.4%

Shares of ASBP traded down $0.26 during mid-day trading on Friday, hitting $5.61. The company had a trading volume of 115,481 shares, compared to its average volume of 321,125. The business’s 50-day simple moving average is $21.35 and its 200-day simple moving average is $90.73. Aspire Biopharma has a 1-year low of $3.31 and a 1-year high of $1,050.36. The stock has a market cap of $953,700.00, a PE ratio of -0.28 and a beta of 0.21.

Institutional Investors Weigh In On Aspire Biopharma

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC increased its stake in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Aspire Biopharma during the third quarter worth about $28,000. Finally, XTX Topco Ltd increased its stake in Aspire Biopharma by 853.2% during the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares during the last quarter. 19.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ASBP. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.